Key result
High immune infiltration, particularly of CD8+ T cells and CD20+ B cells, predicts a poor pathological response to neoadjuvant chemotherapy in patients with undifferentiated pleomorphic sarcomas.
Why the study?
Response variability to neoadjuvant chemotherapy in resectable undifferentiated pleomorphic sarcomas necessitates refined patient selection strategies.
Does the tumor microenvironment predict histological response to neoadjuvant chemotherapy in patients with resectable undifferentiated pleomorphic sarcomas?
Cohort (n=24)
Single-blind
Yes
Does the tumor microenvironment predict histological response to neoadjuvant chemotherapy in patients with resectable undifferentiated pleomorphic sarcomas?
High immune infiltration in undifferentiated pleomorphic sarcomas predicts a poor histological response to neoadjuvant chemotherapy, suggesting these patients may require alternative therapeutic strategies such as chemoimmunotherapy.
Immune infiltration was associated with poor neoadjuvant response in UPS; hypothesis-generating for chemoimmunotherapy trials.
Undifferentiated pleomorphic sarcomas (UPS) represent a prevalent and aggressive subtype of soft tissue sarcomas (STS) in adults. Despite advancements in loco regional treatments, many patients with high grade STS, including UPS, develop metastatic disease. Neoadjuvant chemotherapy is a standard approach to mitigate this risk, but response variability necessitates refined patient selection strategies. This study investigated the correlation between UPS microenvironment and neoadjuvant chemotherapy response in resectable UPS. The NEOSARCOMICS study (NCT02789384) enrolled patients with resectable STS from six sarcoma centers in France. Patients received anthracycline based chemotherapy, followed by surgery. Histological response, gene expression profiling, and multiplex immunohistofluorescence were performed on baseline and post treatment tumor samples. Plasma proteomics was analyzed to identify biomarkers. Good responders to neoadjuvant chemotherapy showed enrichment in genes related to stemness and cell cycle regulation, while poor responders exhibited immune related gene enrichment. Proteomic profiling revealed immune pathway activation and downregulation of cell cycle pathways in non responders. Despite being associated with a good prognosis, high immune infiltration, particularly of CD8 + T cells and CD20 + B cells, predicts a poor response to neoadjuvant chemotherapy in UPS, suggesting the need for alternative therapeutic strategies for patients with inflamed UPS.Ongoing clinical trials are exploring the efficacy of combining chemotherapy with immune checkpoint inhibitors to improve outcomes.
No takes yet. Share an insight, caveat, or question.
Guegan et al. (2024) conducted a cohort in Undifferentiated pleomorphic sarcomas (UPS) (n=24). High immune infiltration (CD8+ T cells and CD20+ B cells) vs. Low immune infiltration was evaluated on Pathological response to neoadjuvant chemotherapy. High immune infiltration, particularly of CD8+ T cells and CD20+ B cells, predicts a poor pathological response to neoadjuvant chemotherapy in patients with undifferentiated pleomorphic sarcomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: